Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Role of Endothelin in Pulmonary Hypertension

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2010 by Brigham and Women's Hospital.
Recruitment status was:  Active, not recruiting
Information provided by:
Brigham and Women's Hospital Identifier:
First received: September 24, 2008
Last updated: May 3, 2010
Last verified: April 2010
The purpose of the study is is to determine the effect, on the lung circulation, of BQ-123, an investigational compound which is not approved by the FDA.

Condition Intervention Phase
Pulmonary Hypertension
Drug: BQ-123
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Role of Endothelin in Pulmonary Hypertension

Resource links provided by NLM:

Further study details as provided by Brigham and Women's Hospital:

Primary Outcome Measures:
  • To determine the contribution of endothelin to pulmonary vasoconstriction [ Time Frame: one testing visit ]

Secondary Outcome Measures:
  • To determine the contribution of endothelin to vasoconstriction in primary and secondary hypertension [ Time Frame: one testing visit ]

Estimated Enrollment: 80
Study Start Date: February 1999
Estimated Study Completion Date: June 2011
Estimated Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: BQ-123
6-120 µg/min

Detailed Description:
Endothelin levels are increased in patients with pulmonary hypertension. We wish to compare the effect of an endothelin antagonist on pulmonary hypertension due to a variety of causes.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • known diagnosis of pulmonary hypertension

Exclusion Criteria:

  • hypertension due to other reasons (not pulmonary)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00759408

United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Brigham and Women's Hospital
Principal Investigator: Mark A Creager, MD Brigham and Women's Hospital
  More Information

Responsible Party: Mark A. Creager, MD, Brigham and Women's Hospital Identifier: NCT00759408     History of Changes
Other Study ID Numbers: 1999-P-003126
Study First Received: September 24, 2008
Last Updated: May 3, 2010

Keywords provided by Brigham and Women's Hospital:
primary pulmonary hypertension
secondary pulmonary hypertension due to left heart failure
secondary pulmonary hypertension due to other causes
patients without pulmonary disease or pulmonary hypertension

Additional relevant MeSH terms:
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Antihypertensive Agents
Endothelin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017